Triasima Portfolio Management inc. Sells 31 Shares of Eli Lilly and Company (NYSE:LLY)

Triasima Portfolio Management inc. reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 9,914 shares of the company’s stock after selling 31 shares during the quarter. Triasima Portfolio Management inc.’s holdings in Eli Lilly and Company were worth $8,976,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. Tidemark LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $29,000. Core Wealth Advisors Inc. grew its position in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after acquiring an additional 32 shares in the last quarter. Lynx Investment Advisory bought a new stake in Eli Lilly and Company during the second quarter worth approximately $32,000. LGT Financial Advisors LLC purchased a new stake in Eli Lilly and Company during the second quarter valued at approximately $36,000. Finally, Frank Rimerman Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $37,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on LLY shares. Argus increased their price target on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. Berenberg Bank increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Guggenheim lifted their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Bank of America increased their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday, August 19th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $961.76.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 1,441 shares of Eli Lilly and Company stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $915.02, for a total value of $1,318,543.82. Following the transaction, the insider now owns 97,367,369 shares in the company, valued at $89,093,089,982.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 737,410 shares of company stock worth $669,719,100 in the last three months. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Down 1.1 %

NYSE LLY traded down $10.04 during trading on Friday, reaching $902.71. 3,439,999 shares of the company’s stock traded hands, compared to its average volume of 3,063,074. Eli Lilly and Company has a 12-month low of $516.57 and a 12-month high of $972.53. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The firm has a market cap of $857.94 billion, a price-to-earnings ratio of 132.95, a price-to-earnings-growth ratio of 2.91 and a beta of 0.42. The company’s 50 day simple moving average is $895.97 and its two-hundred day simple moving average is $827.99.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, sell-side analysts forecast that Eli Lilly and Company will post 16.51 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.58%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s payout ratio is 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.